+32 (0)471 50 59 12
iTeos Therapeutics is a publicly-held (NASDAQ: ITOS), clinical-stage biopharmaceutical company dedicated to extending and improving the lives of cancer patients by designing and developing next generation immunotherapies.
Based in Gosselies, Belgium and Cambridge, MA, iTeos Therapeutics was founded out of the Ludwig Institute for Cancer Research (LICR) and the de Duve Institute (UCLouvain) in 2011.
In March 2020, the Company completed a $125 million Series B2 financing, and in July 2020, we completed our IPO raising over $200million of proceeds.
This additional capital will allow us to continue to develop our clinical pipeline and maintain our investments in our discovery research team to leverage its fantastic science to improve the lives of cancer patients
The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways. EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors.
The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, also designed to engage the Fc gamma receptor (FcγR). An open-label Phase 1/2a clinical trial of EOS-448 is currently ongoing in adult patients with advanced solid tumors.
For more information, please visit www.iteostherapeutics.com.
iTeos Therapeutics has the ambition to become a world-class actor in the sector. To carry on its growth and reinforce its Translational Medicine (TM) department, iTeos Therapeutics is looking for a (m/f) : Senior Scientist – Translational Medicine in immuno-oncology
Within its Translational Medicine (TM) Department, iTeos is currently actively looking for a highly motivated and creative Scientist with expertise in immuno-oncology or immunology research to take a key role supporting the discovery of biomarkers for pharmaco-dynamic analysis and patient selection. The selected candidate will work in close interaction with the Translational Medicine Project Leads, TM scientists and members of the Clinical team to select biomarkers, ensure access to state of the art technologies and evaluate their scientific basis and clinical applicability. He/she will support the development and outsourcing of clinically applicable biomarker assays, ensure the assays are suitably validated/qualified and aid any trouble shooting in technique development. He/she will also be responsible for data analysis and interpretation including running relevant statistical tests. Finally, in close interaction with the TM Lead and the clinical team, he/she will contribute to building the scientific rationale supporting the clinical strategy.
More specifically, the successful candidate will be responsible for:
Nous traitons votre candidature rapidement et de manière strictement confidentielle.